These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 8643041)
1. Function of topoisomerase II and the consequences of inhibition. Davies SM Med Pediatr Oncol Suppl; 1996; 1():12-9. PubMed ID: 8643041 [No Abstract] [Full Text] [Related]
2. DNA topoisomerase II poisons and inhibitors. Capranico G; Giaccone G; D'Incalci M Cancer Chemother Biol Response Modif; 1999; 18():125-43. PubMed ID: 10800480 [No Abstract] [Full Text] [Related]
3. From DNA damage to G2 arrest: the many roles of topoisomerase II. Larsen AK; Escargueil AE; Skladanowski A Prog Cell Cycle Res; 2003; 5():295-300. PubMed ID: 14593724 [TBL] [Abstract][Full Text] [Related]
8. [Chromosome translocations and leukemias induced by inhibitors of topoisomerase II anticarcinogenic drugs]. Dassonneville L; Bailly C Bull Cancer; 1998 Mar; 85(3):254-61. PubMed ID: 9752316 [TBL] [Abstract][Full Text] [Related]
9. Antitumor agents. Part 230: C4'-esters of GL-331 as cytotoxic agents and DNA topoisomerase II inhibitors. Han S; Xiao Z; Bastow KF; Lee KH Bioorg Med Chem Lett; 2004 Jun; 14(11):2979-82. PubMed ID: 15125972 [TBL] [Abstract][Full Text] [Related]
10. Cisplatin-induced endoreduplication in CHO cells: DNA damage and inhibition of topoisomerase II. Cantero G; Pastor N; Mateos S; Campanella C; Cortés F Mutat Res; 2006 Jul; 599(1-2):160-6. PubMed ID: 16574165 [TBL] [Abstract][Full Text] [Related]
11. Topoisomerase II as a target for anticancer chemotherapy. Kaufmann SH; Hancock R Acta Biochim Pol; 1995; 42(4):381-93. PubMed ID: 8852329 [TBL] [Abstract][Full Text] [Related]
12. Novel carbamate derivatives of 4-beta-amino-4'-O-demethyl-4-desoxypodophyllotoxin as inhibitors of topoisomerase II: synthesis and biological evaluation. Duca M; Arimondo PB; Léonce S; Pierré A; Pfeiffer B; Monneret C; Dauzonne D Org Biomol Chem; 2005 Mar; 3(6):1074-80. PubMed ID: 15750651 [TBL] [Abstract][Full Text] [Related]
13. Insights into leukemogenesis from therapy-related leukemia. Pedersen-Bjergaard J N Engl J Med; 2005 Apr; 352(15):1591-4. PubMed ID: 15829541 [No Abstract] [Full Text] [Related]
14. Effect of the anticancer drug oracin on mouse liver topoisomerases I and II. Stuchlík S; Turna J; Miko M J Pharm Pharmacol; 2005 May; 57(5):657-9. PubMed ID: 15901355 [TBL] [Abstract][Full Text] [Related]
15. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249 [TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II poisoning and antineoplastic action by DNA-nonbinding diacetyl and dicarboxaldoxime derivatives of ferrocene. Vashisht Gopal YN; Jayaraju D; Kondapi AK Arch Biochem Biophys; 2000 Apr; 376(1):229-35. PubMed ID: 10729210 [TBL] [Abstract][Full Text] [Related]
18. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310 [TBL] [Abstract][Full Text] [Related]
19. A therapy-related myelodysplastic syndrome with unusual features in a patient treated for acute promyelocytic leukemia. Pecci A; Invernizzi R Haematologica; 2001 Jan; 86(1):102-3. PubMed ID: 11146580 [No Abstract] [Full Text] [Related]
20. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA). Bridewell DJ; Finlay GJ; Baguley BC Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]